|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 190.58 USD | +2.25% |
|
+0.43% | +7.25% |
| 09:14pm | Rothschild & Co Redburn Adjusts AbbVie Price Target to $240 From $239, Maintains Buy Rating | MT |
| 15/07 | Kailera touts late-stage win for weight-loss drug in China | RE |
| Capitalization | 33TCr 28TCr 26TCr 25TCr 45TCr 28,31300Cr 51TCr 3,19700Cr 1,20900Cr 13,24400Cr 1,23500Cr 1,20900Cr 49,02100Cr | P/E ratio 2025 * |
25.6x | P/E ratio 2026 * | 20.2x |
|---|---|---|---|---|---|
| Enterprise value | 38TCr 33TCr 31TCr 29TCr 53TCr 32,96500Cr 59TCr 3,72200Cr 1,40800Cr 15,42000Cr 1,43800Cr 1,40800Cr 57,07600Cr | EV / Sales 2025 * |
6.4x | EV / Sales 2026 * | 5.78x |
| Free-Float |
96.39% | Yield 2025 * |
3.51% | Yield 2026 * | 3.68% |
More valuation ratios
* Estimated data
More news
Last Transcript: AbbVie Inc.
More recommendations
More press releases
More news
| 1 day | +2.15% | ||
| 1 week | +0.22% | ||
| Current month | +2.91% | ||
| 1 month | +0.09% | ||
| 3 months | +11.27% | ||
| 6 months | +9.98% | ||
| Current year | +7.50% |
| 1 week | 185.01 |  | 197.5 |
| 1 month | 181.73 | | 197.5 |
| Current year | 164.39 | | 218.66 |
| 1 year | 163.81 | | 218.66 |
| 3 years | 130.96 | | 218.66 |
| 5 years | 79.11 | | 218.66 |
| 10 years | 45.45 | | 218.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 54 | 01/07/2024 |
Scott Reents
DFI | Director of Finance/CFO | 58 | 23/06/2022 |
Roopal Thakkar
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2003 |
| Director | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 64 | 01/01/2013 |
William Burnside
BRD | Director/Board Member | 73 | 01/01/2013 |
Edward Rapp
BRD | Director/Board Member | 67 | 01/01/2013 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 7.12% | 6 M€ | 0.00% | - | |
| 6.85% | 21 M€ | +3.72% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.15% | +0.22% | +12.90% | +27.72% | 33TCr | ||
| +2.44% | +0.91% | -15.66% | +146.80% | 69TCr | ||
| +6.51% | +6.25% | +9.95% | -4.70% | 37TCr | ||
| +0.12% | -2.13% | -55.30% | +2.59% | 30TCr | ||
| +0.47% | -1.46% | -1.04% | -22.13% | 26TCr | ||
| -0.98% | -2.49% | -3.82% | +15.84% | 23TCr | ||
| -0.57% | +0.71% | -13.75% | -5.95% | 22TCr | ||
| +0.33% | -1.83% | -34.49% | -11.00% | 20TCr | ||
| +1.42% | +0.26% | -10.76% | +21.92% | 16TCr | ||
| +0.22% | -2.91% | -15.88% | -51.10% | 14TCr | ||
| Average | +1.20% | -0.45% | -12.79% | +12.00% | 29.04TCr | |
| Weighted average by Cap. | +1.70% | -0.65% | -11.90% | +34.66% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 5.99TCr 5.16TCr 4.8TCr 4.47TCr 8.22TCr 5,15400Cr 9.2TCr 58TCr 22TCr 2,41100Cr 22TCr 22TCr 8,92300Cr | 6.48TCr 5.58TCr 5.19TCr 4.84TCr 8.9TCr 5,57400Cr 9.95TCr 63TCr 24TCr 2,60800Cr 24TCr 24TCr 9,65200Cr |
| Net income | 1.11TCr 953.72Cr 887.42Cr 826.85Cr 1.52TCr 95TCr 1.7TCr 11TCr 4.07TCr 45TCr 4.15TCr 4.07TCr 1,64900Cr | 1.5TCr 1.29TCr 1.2TCr 1.12TCr 2.06TCr 1,29100Cr 2.3TCr 15TCr 5.51TCr 60TCr 5.63TCr 5.51TCr 2,23400Cr |
| Net Debt | 5.41TCr 4.66TCr 4.33TCr 4.04TCr 7.42TCr 4,65200Cr 8.3TCr 53TCr 20TCr 2,17600Cr 20TCr 20TCr 8,05500Cr | 4.54TCr 3.91TCr 3.64TCr 3.39TCr 6.23TCr 3,90500Cr 6.97TCr 44TCr 17TCr 1,82700Cr 17TCr 17TCr 6,76200Cr |
More financial data
* Estimated data
Employees
55,000
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/25/17 | 190.58 $ | +2.25% | 62,02,126 |
| 15/25/15 | 186.39 $ | -2.68% | 67,29,235 |
| 14/25/14 | 191.52 $ | -0.48% | 40,72,779 |
| 11/25/11 | 192.45 $ | -1.31% | 49,90,981 |
| 10/25/10 | 195.00 $ | +2.30% | 60,49,615 |
Delayed Quote Nyse, July 16, 2025 at 09:32 pm IST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
186.39USD
Average target price
209.16USD
Spread / Average Target
+12.22%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABBV Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition